Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 9:41 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 649–672 of 3,775 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Type 2 Diabetes Clear all
Completed Not applicable Interventional Results available

Stepping-down Approach in Patients With Chronic Poorly-controlled Diabetes on Advanced Insulin Therapy?

NCT02846233
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
GLP1 receptor agonist, basal insulin, SGLT2 inhibitor, Metformin
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
21 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Fresno, California
Source: ClinicalTrials.gov public record
Updated Nov 10, 2020 · Synced Oct 25, 2026, 9:41 AM EDT
Completed Not applicable Interventional

A Mindfulness-based Intervention for Adolescents With Prediabetes or Type 2 Diabetes

NCT07270900
View directory record Official record
Conditions
Type 2 Diabetes, Prediabetes
Interventions
Mindfulness Based Group
Procedure
Lead sponsor
Indiana University
Other
Eligibility
12 Years to 18 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 8, 2025 · Synced Oct 25, 2026, 9:41 AM EDT
Completed Phase 4 Interventional

Adrenocorticotropic Hormone (ACTH) Treatment of Nephrotic Range Proteinuria in Diabetic Nephropathy (NRDN)

NCT01028287
View directory record Official record
Conditions
Diabetic Nephropathy, Nephrotic Syndrome
Interventions
ACTH
Drug
Lead sponsor
Southeast Renal Research Institute
Other
Eligibility
18 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Chattanooga, Tennessee
Source: ClinicalTrials.gov public record
Updated May 31, 2013 · Synced Oct 25, 2026, 9:41 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Relationship Between Insulin Resistance and Statin Induced Type 2 Diabetes, and Integrative Personal Omics Profiling

NCT02437084
View directory record Official record
Conditions
Hyperlipidemia, Insulin Resistance, Type 2 Diabetes
Interventions
Atorvastatin
Drug
Lead sponsor
Stanford University
Other
Eligibility
30 Years to 70 Years
Enrollment
115 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2020
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 6, 2021 · Synced Oct 25, 2026, 9:41 AM EDT
Recruiting Phase 3 Interventional

A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes

NCT07668336
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Orforglipron, Dulaglutide
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
10 Years to 17 Years
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
17
States / cities
Sacramento, California • San Diego, California • Stamford, Connecticut + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 25, 2026, 9:41 AM EDT
Completed Phase 3 Interventional Results available

Study of VI-0521 Compared to Placebo in Treatment of Diabetes and Obesity in Adults With Obesity-Related Co-Morbid Conditions

NCT00553787
View directory record Official record
Conditions
Obesity, Type 2 Diabetes
Interventions
VI-0521
Drug
Lead sponsor
VIVUS LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
2,487 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
6
States / cities
Birmingham, Alabama • Ridgefield, Connecticut • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2012 · Synced Oct 25, 2026, 9:41 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Mobile Diabetes Prevention for Hispanics Living in Rural Areas

NCT05856149
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Mobile Diabetes Prevention Program
Behavioral
Lead sponsor
ISA Associates, Inc.
Other
Eligibility
18 Years to 99 Years
Enrollment
179 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Alice, Texas
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Oct 25, 2026, 9:41 AM EDT
Completed Not applicable Interventional

Boosting Emotions & Happiness in Outpatients Living With Diabetes

NCT02736084
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Positive Psychology
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 13, 2016 · Synced Oct 25, 2026, 9:41 AM EDT
Completed Phase 3 Interventional Results available

A Study In Patients With Type 2 Diabetes Mellitus

NCT00256867
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
GSK523338
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
369 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
43
States / cities
Tucson, Arizona • Fresno, California • Wheat Ridge, Colorado + 38 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2018 · Synced Oct 25, 2026, 9:41 AM EDT
Recruiting Not applicable Interventional

Achieving Routine Intervention and Screening for Emotional Health

NCT06887049
View directory record Official record
Conditions
Type 2 Diabetes Mellitus (T2DM), Diabetes Distress
Interventions
ARISE Learning Community Diabetes Distress Screening and Intervention, ARISE Enhanced Care brief training
Behavioral
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
880 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 25, 2026, 9:41 AM EDT
Terminated Phase 2 Interventional Results available

Dose-Ranging Study to Evaluate Efficacy and Safety of Weekly CJC-1134-PC in Patients With T2DM on Metformin Monotherapy

NCT01514149
View directory record Official record
Conditions
Type 2 Diabetes Mellitus (T2DM)
Interventions
CJC-1134-PC Injection, Weekly placebo for CJC-1134-PC Injection
Drug
Lead sponsor
ConjuChem
Industry
Eligibility
18 Years to 70 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
19
States / cities
Phoenix, Arizona • Inglewood, California • Tarzana, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2017 · Synced Oct 25, 2026, 9:41 AM EDT
Completed Phase 3 Interventional Results available

A Study Assessing Saxagliptin Treatment in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise

NCT00374907
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Saxagliptin, Placebo, Metformin (blinded), Metformin (open-label)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
3
States / cities
San Diego, California • Baton Rouge, Louisiana • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 7, 2015 · Synced Oct 25, 2026, 9:41 AM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Safety and Efficacy of Oral Insulin in T2DM Patients With Nonalcoholic Steatohepatitis (NASH)

NCT04618744
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, NASH - Nonalcoholic Steatohepatitis
Interventions
ORMD-0801 (Insulin) capsule 8 mg BD, Placebo
Drug · Other
Lead sponsor
Oramed, Ltd.
Industry
Eligibility
18 Years to 70 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Tustin, California
Source: ClinicalTrials.gov public record
Updated Aug 7, 2024 · Synced Oct 25, 2026, 9:41 AM EDT
Completed Phase 1 Interventional

Effects of Treating Vitamin D Deficiency in Poorly Controlled Type 2 Diabetes

NCT01855321
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Vitamin D, Placebo
Drug
Lead sponsor
University of Florida
Other
Eligibility
30 Years to 65 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 26, 2015 · Synced Oct 25, 2026, 9:41 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Conditional Cash Transfer Intervention to Improve T2DM

NCT05559892
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
DM-CCT, DM-UCT
Behavioral
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced Oct 25, 2026, 9:41 AM EDT
Completed Not applicable Interventional

Improving Glycemic Control Using a Virtual Weight Control Program and Continuous Glucose Monitoring

NCT05935514
View directory record Official record
Conditions
Diabetes Mellitus, Type 2 Diabetes, Obesity
Interventions
WW Intervention, Usual Care
Behavioral
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
18 Years to 69 Years
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
3
States / cities
Stanford, California • Baton Rouge, Louisiana • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Oct 25, 2026, 9:41 AM EDT
Recruiting Not applicable Interventional

Remote Physical Activity Programming to Improve Outcomes in Cancer Survivors With and Without Type 2 Diabetes

NCT06725953
View directory record Official record
Conditions
Cancer Survivorship, Chemotherapy Side Effects
Interventions
Social Cognitive Theory-based, Technology-delivered Physical Activity Program
Behavioral
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 25, 2026, 9:41 AM EDT
Completed Phase 2 Interventional

A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy

NCT06797869
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Diabetic Peripheral Neuropathy
Interventions
CagriSema (Cagrilintide B and Semaglutide I), Placebo matched to CagriSema (Cagrilintide B and Semaglutide I)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
20
States / cities
La Mesa, California • San Diego, California • Miami, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 25, 2026, 9:41 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

A Family Dyad-focused Diabetes Self-Management Intervention for African American Adults

NCT05905575
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Family dyad diabetes intervention
Behavioral
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 90 Years
Enrollment
208 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Oct 25, 2026, 9:41 AM EDT
Terminated Not applicable Interventional

Developing Affective HeaLth to Improve Adherence to Health Behaviors in Diabetes (DAHLIA II)

NCT04068805
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Happify
Behavioral
Lead sponsor
Happify Inc.
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 19, 2022 · Synced Oct 25, 2026, 9:41 AM EDT
Completed Not applicable Interventional

Preventing T2DM After GDM With Immediate Postpartum Screening

NCT06457139
View directory record Official record
Conditions
Gestational Diabetes, Type 2 Diabetes
Interventions
Glucose tolerance test (2 hour), Active Comparator
Diagnostic Test · Other
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years and older · Female only
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 25, 2026, 9:41 AM EDT
Completed Not applicable Interventional

Dance Dance Revolution (DDR) in Type 2 Diabetes

NCT00851019
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
DDR, Treadmill
Behavioral
Lead sponsor
Charles Drew University of Medicine and Science
Other
Eligibility
18 Years to 65 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 27, 2013 · Synced Oct 25, 2026, 9:41 AM EDT
Completed Phase 3 Interventional Results available

GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin

NCT00763451
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Lixisenatide (AVE0010), Placebo, Pen auto-injector, Metformin
Drug · Device
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
484 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 14, 2016 · Synced Oct 25, 2026, 9:41 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Examination of Dermatologic Effects From Subcutaneous Injections of ISIS 113715

NCT00365781
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
ISIS 113715
Drug
Lead sponsor
Ionis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Oct 17, 2007 · Synced Oct 25, 2026, 9:41 AM EDT